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Introduction
Response to treatment is dependent upon
effective blood and tissue concentrations of the
drugs administered, and these concentrations are,
in turn, dependent on a number of factors such as
absorption from the site of administration,
distribution metabolism and excretion. Most anti-
tuberculosis drugs are administered orally and
are known to be really absorbed from the gastro-
intestinal tract. Fully oral regimens containing
drugs such as isoniazid, rifampicin, pyrazinamide
and ethambutol have been shown to be highly
effective in the treatment of pulmonary
tuberculosis and several extra-pulmonary forms
of the disease such as tuberculous lymphadenitis
and spinal tuberculosis. The efficacy of these oral
regimens in patients with abdominal tuberculosis,
including those with intestinal tuberculosis, is
now being examined in a controlled clinical trial
at the Tuberculosis Research Centre, Madras.
Tuberculosis of the gastro-intestinal tract could
lead to a destruction of the mucosal membrane
resulting in a decreased absorption of drugs and
nutrients. Further, bacterial overgrowth in the
intestines has been shown to lead to the
malabsorption of a number of substances
(Theodossi and Gazzard, 1984). An investigation
was, therefore, undertaken to study the
absorption of isoniazid and rifampicin, two of the
most commonly used anti-tuberculosis drugs, in
patients with intestinal tuberculosis and compare
the findings with those obtained in patients with
pulmonary tuberculosis. In addition, the
absorption of D-xylose, which has widely been
used to assess the absorptive capacity of the
proximal small intestine (Chanarin and Bennett,
1962; Sammons et al., 1967), was also studied; this
report presents the findings.
Material and Methods
Patients
Intestinal tuberculosis : Twelve patients (7 male
and 5 female), aged 13 to 45 years, with a mean
body-weight of 36.7 kg (range : 23-52 kg) were
admitted to the study. The diagnosis of intestinal
tuberculosis was made on the basis of
radiological, histopathological and bacteriological
findings. Duodenum was predominantly involved
in 1 patient, ileum in 1, ileocaecum in 2, and
ileocaecum in combination with other viscera
such as peritoneum, colon, liver or mesenteric
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lymph nodes in the remaining 8 patients. Further,
4 of the 12 patients had surgical resection of part
of the affected portion of the intestines (right
hemicolectomy in 2 patients and ileocaecal
resection in 2 others).
Pulmonary tuberculosis : Eighteen sputum
smear-positive patients (15 male and 3 female),
aged 14 to 44 years with a mean body-weight of
41.5kg (range : 34-51 kg) and with no obvious
clinical evidence of gastro-intestinal dysfunction
were used as controls.
The renal and hepatic functions, as assessed by
plasma creatinine concentrations, and by the
activities of AST and ALT, respectively, were
normal in all patients in both groups.
Determination of the acetylator phenotype : The
acetylator phenotype was determined on the basis
of the molar ratio of acetylisoniazid to isoniazid
in urine. The ratio was determined in urine
collected over the period 5-6 hours after a
uniform oral dose of isoniazid 300 mg in patients
with intestinal tuberculosis (Raghupati Sarma et
al., 1976), and over the period 24-25 hours
following an oral dose of 30 mg/kg of a slow-
release preparation  of isoniazid (“matrix
isoniazid”) in patients with pulmonary
tuberculosis (Kailasam et al., 1975).
Conduct of the investigation : Isoniazid 300 mg
and rifampicin 10 mg/kg were administered on
an empty stomach to both groups of patients.
Half-an-hour later, a uniform oral dose-of D-
xylose 5 g was administered. Blood at 1, 2, 3, 6
and 8 hours, and urine excreted over the periods
0-½ hour and then at 2-hourly periods upto 8½
hours after administration of the anti-tuberculosis
drugs were collected in plain bottles. (A small
volume of the blood collected at 2 hours, i.e., 1½
hours after xylose administration, was transferred
to a bottle containing oxalate and fluoride for
estimation of blood xylose concentrations).
Serum was separated from the blood samples and
stored at –20°C for a period not exceeding 3 days
for the determination of the concentrations of
isoniazid and rifampicin. For estimation of xylose,
a protein-free filtrate (proteins having been
precipitated from 1 ml of blood diluted with 7 ml
water by the addition of 1 ml portions of 5
percent zinc sulphate and 5 percent barium
hydroxide solutions) of the oxalated blood sample
collected at 2 hours was stored at –-20°C for a
period not exceeding 3 days. The volume of the
urine samples excreted was noted and aliquots
stored at –20°C for a period not exceeding 7 days
before estimations of isoniazid and its
metabolites were undertaken; xylose was
estimated only in those samples collected after
administration of D-xylose (i.e. from ½ hour to
8½ hours).
Serum concentrations of isoniazid were
estimated by a standard spectrophotometric
method involving condensation with vanillin (Rao
et al, 1971). Serum rifampicin concentrations
were determined by the plate diffusion assay of
Dickinson et al. (1974), employing a strain of
Staphylococcus aureus (Sub group I, NCTC
10702), resistant to streptomycin and other
antibiotics. Rifampicin standards ranging from
0.04 to 1.28 µg/ml were set up in quadruplicate,
and the concentrations of the drug in the samples
(set up in quadruplicate in dilutions of 1 in 5 and
1 in 10) were obtained from the regression line of
the diameter of the zone of inhibition on log
concentration of the standard. The proportion of
the dose of isoniazid excreted as isonicotinyl
compounds (i.e. isoniazid, acetylisoniazid,
isonicotinic acid,. isonicotinyl glycine) in urine
excreted over the period 0-8½ hours was
estimated after acid hydrolysis of the urine
samples by which all isonicotinyl compounds
were converted to isonicotinic acid (Ellard and
Gammon, 1976). D-xylose in the protein-free
filtrates and the urine collections was estimated
by a standard procedure involving reaction with
p-bromoaniline (Tietz, 1976), slightly modified to
eliminate any possible interference due to
rifampicin. (The protein-free filtrates and the
suitably diluted urine specimens (1 in 10, 1 in 25
or 1 in 50) were extracted thrice with 3 ml
portions of chloroform and the organic layer
containing rifampicin was discarded). All
estimations were undertaken after coding the
specimens.
Calculation of pharmacokinetic variables : The
peak concentration was the geometric mean of
the highest concentration in individual patients.
Exposure to isoniazid was calculated as the area
under the time-concentration curve (AUC) from
a plot of concentration versus time as linear co-
ordinates. The serum half-lives of isoniazid and
rifampicin were calculated from the terminal
phase of the time-concentration curves.
Results
As mentioned earlier, of the 12 patients with
intestinal tuberculosis, 4 (3 slow acetylators) had
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resection of a part of the diseased portion of their
intestines, while the remaining 8 (7 slow
acetylators) did not. The findings in the 2 groups
were similar; thus, the mean values for peak
concentration, exposure and the serum half-life of
rifampicin were 9.5 and 10.2 µg/ml, 65 and 60
µg/ml. hours, and 4.4 and 3.7 hours, in patients
who had resection and in those who did not,
respectively. None of the differences was
significant (P>0.2); the findings in the two groups
have therefore been amalgamated. (The findings
for isoniazid have not been compared due to
differences in the proportions of rapid acetylators
in the 2 groups).
Of the 12 patients with intestinal tuberculosis,
10 were slow acetylators and the remaining 2,
rapid acetylators of isoniazid, of the 18 patients
with pulmonary tuberculosis, 8 were slow and 10
were rapid acetylators. The mean dosage of
isoniazid administered to the 10 slow acetylators
with intestinal tuberculosis was 8.5 mg/kg while
that administered to 8 slow acetylators with
pulmonary tuberculosis was 7.1 mg/kg; the mean
dosages of isoniazid in rapid acetylators in the 2
groups were 8.5 and 7.5 mg/kg, respectively. The
mean dosages of rifampicin in the two groups of
tuberculous patients were 9.9 and 10.1 mg/kg,
respectively, and the mean dosage of xylose was
142 mg/kg in patients with intestinal tuberculosis
and 122 mg/kg in those with pulmonary
tuberculosis.
The distribution of patients by-the time after
 drug administration at which the highest serum
concentrations of isoniazid and rifampicin were
observed was similar in the two groups of
patients. Thus, for isoniazid (amalgamating the
findings in the slow and the rapid acetylators),
among the 12 patients with intestinal tuberculosis,
highest concentrations were observed in 8 at 1
hour, in 3 at 2 hours and in 1 at 3 hours, and in 15,
1 and 2, respectively among the 18 patients with
pulmonary tuberculosis. For rifampicin, the
corresponding numbers were 3, 6 and 3 in
patients with intestinal tuberculosis, and 5, 8 and
5 in those with pulmonary tuberculosis.
The highest concentrations of isoniazid were
attained by the 3rd hour in all the patients and the
concentrations fell exponentially thereafter (Fig.
1). In slow acetylators, while the peak
concentration for isoniazid was higher (P = 0.04),
the mean serum half-life was slightly lower
(P = 0.05) in patients with intestinal tuberculosis
Fig. 1. Serial serum isoniazid concentrations (±
standard error of the mean) in slow acetylators
(solid line,       )  and rapid acetylators
(broken line, -------) among patients with
intestinal tuberculosis (closed circles, · ) and
those with pulmonary tuberculosis (open
circles, 0).
than in those with pulmonary tuberculosis (Table
1); the difference between the mean values for
exposure to isoniazid was not significant (P>0.1).
None of the differences in the 3 parameters was
significant (P > 0.2) between the two groups of
patients in the rapid acetylators.
The mean proportion’ of dose excreted as
isonicotinyl compounds in urine collected over
the 0-8½ hour period after administration of- the
anti-tuberculosis drugs (after amalgamating the
findings in slow and rapid acetylators, which were
similar) was 56 percent in patients with intestinal
tuberculosis and 60 percent in those with
pulmonary tuberculosis (P > 0.2).
The highest concentrations of rifampicin were
attained by the 3rd hour in both groups of
patients and there was an exponential fall
thereafter (Fig. 2). The peak concentration
(Table 2) was about 30 percent higher in patients
with intestinal tuberculosis than in those with
pulmonary tuberculosis (P = 0.04); the differences
in the exposure to rifampicin and its serum half-
life were, however, not significant (P > 0.2).
The mean blood xylose concentrations at 1%
hours and the mean proportions of the dose of
xylose excreted over the periods 0-2 and 0-8 hours
after administration of D-xylose in the 2 groups
of patients are presented in Table 3. The mean
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Table 1. Some phatmacokinetic variables  of isoniazid  in patients with intestinal tuberrulosis  and pulmonary
hdbercuiosiis!
Slow acetylators
Pharmacokinetic variable ~ Intestinal TB Pulmonary TB
  P e a k  tM*
concentration @g/ml) (6.4-15.0) (4.E.9)
Exposure
(pg/ml.hours) (3E2) (2&)
Serum half-life
(hours) (2.E3)  . (2.E.4)
No. of patients 10 8
Rapid acetylators
Intestinal TB Pulmonary TB
(5.G) (4.L)
(It&) (1%)
(l.E.9) (LZ4)
2 10
*Geometric mean with range in parentheses.
,
Table 2. Some phannacokinetic  variables of rifnmpicin
in patients with intestinal tuberculosis and pulmonary
tuberculosis
-,
Pharmacokinetic Intestinal TB Pknonary  TE?
variable
pal! 10.0+
concentraeion  (fig/ml)  (6.0-16.0) (4.Z.4)
Exposure
.(lrg/mi.hours) (3%)
Serum half-life
(hours) (2.E.2) ( 2 . k )
No. of patients 12 18
*Geometric mean with range in parentheses.
E0 1
2 I I I I I
1 2 3 6 0
Hours after drug administration
Fig. 2. Serial serum rifampicin concentrations in
patients with intestinal tuberculosis (closed
circles, 0) and those with pulmonary
tuberculosis (open circles, 0).
blood concentration was about 23 percent higher
in patients with intestinal tuberculosis than in
those with pulmonary tuberculosis (P = 0.07). On
the contrary, the mean proportion of dose of
xylose excreted in urine was lower in the former
than in the latter, the difference being of the
order of 7 percent over the O-2 hour period
(P >’ 0.2), and about I.3 percent over the O-8 hour
period (P = 0.04).
Discussion
Absorption of drugs by transport across
biological membranes in the stomach and the
intestines is essentially by passive diffusioxr.  The
basic requirements of such. a transport are lipid
Table 3. Blood xyiose concentmtions and proportions of
dose of xyiose excreted in wine in patients with intestinal
tuberculosis and pubnonary  tuberrulosis
Body-fluid Period of Intestinal Pulmonary
collection* TB l-B
Blood
Concentration 1!4
(w/d9
Urine
17.5++ 14.2
(6.2-24.7) (8.0-23.1)
Proportion of O-2 15.0 16.2
dose excreted (%) (7.7-20.2) (7.~26.7)
o-8 34.8 40.2
;26.0-44.4) (29.5543)
No. of patients 12 18
*Hours after administration of D-xylose
**Mean with range in parentheses
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solubility and degree of ionisation at physiological
pH of the drug, with the absorption being greater
for compounds which are ionised less. Other
factors that could influence the rate of absorption
are molecular weight and configuration solubility
of the drugs in body fluids and particle size. Most
anti-tuberculosis drugs are compounds with a low.
molecular weight; they are lipid soluble and are
weak electrolytes, and hence are readily absorbed
from the gastro-intestinal tract. Results presented
in this report demonstrate that the absorption of
isoniazid and rifampicin is not affected in patients
with intestinal tuberculosis. Indeed, the mean
peak serum concentrations of isoniazid (in slow
acetylators) and rifampicin were slightly higher in
patients with intestinal tuberculosis than in those
with pulmonary tuberculosis. Further, the
similarity in the distribution of patients by the
time-point of blood collection at which the
highest serum concentrations of isoniazid and
rifampicin were observed suggests that the
absorption of both drugs in patients with
intestinal tuberculosis is as good as that in those
with pulmonary tuberculosis.
  The jejunal portion of the intestines was not
affected in any of the patients admitted to the
study, and as such the absorption of D- xylose,
which can detect only jejunal malabsorption, was
not impaired in any of the patients. Investigations
undertaken on an earlier occasion in healthy
subjects (unpublished findings) had shown that
the mean blood xylose concentration at 1½ hours
and the mean proportion of the dose excreted
over the period 0-2 hours after ingestion of D-
xylose 5 g were 15.6 mg/dl and 17.0 percent,
respectively, values similar to those observed in
the present study in the two groups of
tuberculous patients.
It has been demonstrated that surgical
procedures such as partial gastric and duodenal
resection (Robson and Sullivan, 1963), and
jejunoileal by-pass (Bruce and Wise, 1976; Polk,
Tenenbaum and Kline, 1978) did not significantly  
alter the absorption of isoniazid. Similarly, for  
rifampicin, sub-total or total gastrectomies,
coeliac disease or small-bowel diverticulosis, did
not affect the absorption of the drug as assessed
by comparison of the exposure to the drug
(AUC) between these patients and healthy
subjects (Kenny and Strates, 1981). Further, the
absorption of rifampicin was also shown to be
normal in patients with Crohn’s disease, a
chronic, granulomatous inflammation affecting
the distal portion of the ileum (Kenny and
Strates, 1981).
Tuberculosis rarely affects the stomach and
the proximal loops of the small intestines. Thus,
of the 106 patients with intestinal tuberculosis
admitted to the controlled clinical trial of the
treatment of abdominal tuberculosis at our
Centre, none had tuberculosis of the stomach and
the duodenum was affected in only 3 patients
(unpublished findings). In the present
investigation, only one of the 12 patients admitted
had duodenal tuberculosis; further, in the 4
patients who had had resection of the affected
portion of the intestines, only part of the distal
portions of ‘the small intestines were surgically
removed. It is possible that isoniazid and
rifampicin are readily absorbed from all sites of
the gastro-intestinal tract, and the absorption of
these drugs is not affected in patients with
intestinal tuberculosis irrespective of the site of
involvement.
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